Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial

Beitrag in einer Fachzeitschrift


Details zur Publikation

Autor(en): Suttorp M, Schulze P, Glauche I, Goehring G, Von Neuhoff N, Metzler M, Sedlacek P, De Bont ESJM, Balduzzi A, Lausen B, Aleinikova O, Sufliarska S, Henze G, Strauss G, Eggert A, Kremens B, Groll AH, Berthold F, Klein C, Gross-Wieltsch U, Sykora KW, Borkhardt A, Kulozik AE, Schrappe M, Nowasz C, Krumbholz M, Tauer JT, Claviez A, Harbott J, Kreipe HH, Schlegelberger B, Thiede C
Zeitschrift: Leukemia
Jahr der Veröffentlichung: 2018
Band: 32
Heftnummer: 7
Seitenbereich: 1657-1669
ISSN: 0887-6924


Abstract

A total of 156 patients (age range 1.3-18.0 years, median 13.2 years; 91 (58.3%) male) with newly diagnosed CML (N = 146 chronic phase (CML-CP), N = 3 accelerated phase (CML-AP), N = 7 blastic phase (CML-BP)) received imatinib up-front (300, 400, 500 mg/m2, respectively) within a prospective phase III trial. Therapy response, progression-free survival, causes of treatment failure, and side effects were analyzed in 148 children and adolescents with complete data. Event-free survival rate by 18 months for patients in CML-CP (median follow-up time 25 months, range: 1-120) was 97% (95% CI, 94.2-99.9%). According to the 2006 ELN-criteria complete hematologic response by month 3, complete cytogenetic response (CCyR) by month 12, and major molecular response (MMR) by month 18 were achieved in 98, 63, and 59% of the patients, respectively. By month 36, 86% of the patients achieved CCyR and 74% achieved MMR. Thirty-eight patients (27%) experienced imatinib failure because of unsatisfactory response or intolerance (N = 9). In all, 28/148 patients (19%) underwent stem cell transplantation (SCT). In the SCT sub-cohort 2/23 patients diagnosed in CML-CP, 0/1 in CML-AP, and 2/4 in CML-BP, respectively, died of relapse (N = 3) or SCT-related complications (N = 2). This large pediatric trial extends and confirms data from smaller series that first-line imatinib in children is highly effective.


FAU-Autoren / FAU-Herausgeber

Krumbholz, Manuela Dr. rer. nat.
Kinder- und Jugendklinik
Metzler, Markus PD Dr.
Professur für Kinder- und Jugendmedizin mit dem Schwerpunkt Pädiatrische Onkologie und Hämatologie


Autor(en) der externen Einrichtung(en)
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Charité - Universitätsmedizin Berlin
Comenius University Bratislava
Hannover Medical School / Medizinische Hochschule Hannover (MHH)
Heinrich-Heine-Universität Düsseldorf
Klinikum Stuttgart
Ludwig-Maximilians-Universität (LMU)
Rigshospitalet
Technische Universität Dresden
Universitätsklinikum Essen
Universitätsklinikum Gießen und Marburg (UKGM)
Universitätsklinikum Heidelberg
Universitätsklinikum Köln
Universitätsklinikum Münster
Universitätsklinikum Schleswig-Holstein (UKSH)
University Medical Center Groningen (UMCG) / Universitair Medisch Centrum Groningen
University of Milano-Bicocca / Università degli Studi di Milano-Bicocca, UNIMIB
Univerzita Karlova v Praze / Charles University in Prague


Zitierweisen

APA:
Suttorp, M., Schulze, P., Glauche, I., Goehring, G., Von Neuhoff, N., Metzler, M.,... Thiede, C. (2018). Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. Leukemia, 32(7), 1657-1669. https://dx.doi.org/10.1038/s41375-018-0179-9

MLA:
Suttorp, Meinolf, et al. "Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial." Leukemia 32.7 (2018): 1657-1669.

BibTeX: 

Zuletzt aktualisiert 2019-10-04 um 05:08